Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
PaperCitations, authors & open-access status
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 22 citations, 2023 year and hybrid oa status.
22
Citations
2023
Year
hybrid
OA Status